News | December 04, 2024
Biocon celebrates 46th Founder’s Day
The celebrations began with the unveiling of the Biocon Anthem
The celebrations began with the unveiling of the Biocon Anthem
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Subscribe To Our Newsletter & Stay Updated
